Skip to main content

Table 4 Odds ratios of the increased risk of developing neuropathy per 100 mg unit increase (or 1 AUC for carboplatin) of chemotherapy dose (generalized estimating equation)

From: Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

  Abnormal
Drug NCI CTCAE motor NCI CTCAE sensory WHO CIPN Cotton wool Monofilament
Oxaliplatin-based regimens (n = 27, observations = 196) 1.15 (0.90, 1.47) 1.25 (0.94, 1.67) 1.13 (0.95, 1.34) 1.32* (1.06, 1.64) 1.42* (1.06, 1.89)
Carboplatin AUC (in 1 unit) (n = 88, observations = 657) 1.03 (0.98, 1.08) 1.06* (1.01, 1.10) 0.98 (0.93, 1.03) 0.93* (0.88, 0.99) 0.96 (0.92, 1.01)
Cisplatin-based regimens (n = 70, observations = 362) 0.89 (0.55, 1.46) 0.90 (0.55, 1.49) 1.43 (0.94, 2.19) 1.28 (0.57, 2.91) 1.37 (0.86, 2.17)
Paclitaxel-based regimens (n = 83, observations = 621) 1.02 (0.83, 1.25) 1.01 (0.85, 1.20) 1.01 (0.92, 1.11) 0.91 (0.80, 1.04) 0.94 (0.84, 1.06)
Docetaxel-based regimens (n = 151, observations = 1167) 0.96 (0.69, 1.32) 1.03 (0.69, 1.52) 1.36 (0.91, 2.04) 2.12 (0.93, 4.81) 1.47 (0.96, 2.25)
  1. *Significant at 5% level